Table 1.
Characteristics of the included studies
| Reference | Year | Source | Patients (N) | Stage | Mutation number (%) | Mutation type (locus/exon) | Gene testing method | Statistical methods |
|---|---|---|---|---|---|---|---|---|
| Na et al19 | 2007 | Korea | 133 | I–III | EGFR 32 (24) | EGFR (18–21) | SEQ | Univariate |
| Suehisa et al20 | 2007 | Japan | 187 | I–IIIA | EGFR 79 (43) | EGFR (19, 21) | PCR, SEQ | Multivariate |
| Marks et al21 | 2008 | USA | 296 | I–III | EGFR 40 (13.6), KRAS 50 (17) | EGFR (18–21), KRAS (2) | PCR, SEQ | Multivariate |
| Kobayashi et al22 | 2008 | Japan | 127 | I | EGFR 64 (50.4) | EGFR (19, 21) | Mutant-enriched PCR | Multivariate |
| Woo et al24 | 2009 | Japan | 190 | I | KRAS 24 (12.6) | KRAS (2) | PCR | Multivariate |
| Hosokawa et al23 | 2009 | Japan | 93 | I–III | EGFR 37 (40) | EGFR (18–21) | PCR, SEQ | Univariate |
| Lee et al25 | 2009 | Korea | 117 | I–IIIA | EGFR 48 (41.8) | EGFR (18–21) | Nested PCR | Univariate |
| Galleges Ruiz et al26 | 2009 | The Netherlands | 178 | I–III | KRAS 25 (14) | No data | Nested PCR | Multivariate |
| Kosaka et al27 | 2009 | Japan | 397 | I–IV | EGFR 196 (49), KRAS 142 (38) | EGFR (18–21), KRAS (2) | PCR, SEQ | Multivariate |
| Liu et al28 | 2010 | Taiwan (China) | 164 | I–IIIA | EGFR 52 (31.7), KRAS 7 (4.3) | EGFR (18–21), KRAS (2, 3) | SEQ | Multivariate |
| Tsao et al29 | 2011 | Canada | 436 | IB–II | EGFR 27 (12.2) | EGFR (19, 21) | ARMS | Multivariate |
| D’Angelo et al30 | 2012 | USA | 1,118 | I–III | EGFR 896 (80.1), KRAS 841 (75.2) | EGFR (19, 21), KRAS (2) | PCR, SEQ | Multivariate |
| Kim et al31 | 2012 | Korea | 229 | I–IV | EGFR 110 (48), KRAS 8 (3.5) | EGFR (18–21), KRAS (2) | Nested PCR | Multivariate |
| Scoccianti et al32 | 2012 | Europe (multinational) | 152 | I–IV | EGFR 18 (11.8) | EGFR (18–21) | PCR, SEQ | Multivariate |
| 249 | I–IV | KRAS 46 (18.5) | KRAS (2) | Mutant-enriched PCR, SEQ | Multivariate | |||
| Sonobe et al33 | 2012 | Japan | 180 | I–III | EGFR 148 (82.2) | EGFR (18–21) | RT-PCR | Multivariate |
| Izar et al13 | 2013 | USA | 307 | I | EGFR 62 (19.9), KRAS 127 (40.7) | EGFR (18–21), KRAS (2) | SEQ, multiplex PCR | Multivariate |
| Sun et al35 | 2013 | China | 150 | IIIA | EGFR 43 (28.7) | EGFR (19, 21) | RT-PCR | Multivariate |
| Maki et al34 | 2013 | Japan | 105 | IA | EGFR 51 (49) | No data | PCR, SEQ | Univariate |
| Kim et al11 | 2013 | Korea | 863 | IB–IIA | EGFR 354 (41) | EGFR (18–21) | PCR, SEQ | Univariate |
| Ragusa et al36 | 2014 | Italy | 230 | I–III | EGFR 22 (9.6), KRAS 39 (16.9) | EGFR (18–21), KRAS (2, 3) | Nested PCR | Univariate |
| Ohba et al37 | 2014 | Japan | 354 | I | EGFR 122 (34.4) | EGFR (19, 21) | PCR, SEQ (EGFR)/RFLP (KRAS) | Univariate |
| Liu et al38 | 2014 | China | 131 | I–IIIA | EGFR 58 (44.3) | EGFR (18–21) | Nested PCR | Multivariate |
| Ayyoub et al39 | 2014 | Spain | 216 | I–III | EGFR 21 (9.7), KRAS 29 (3.4) | EGFR (18–21), KRAS (2) | RT-PCR | Univariate |
| Kudo et al40 | 2015 | Japan | 198 | I–III | EGFR 57 (28.7) | EGFR (18, 19, 21) | PCR, SEQ | Univariate |
| Nadal et al41 | 2015 | USA | 179 | I–IV | KRAS 85 (47.5) | KRAS (2) | PCR, SEQ | Multivariate |
| Nishii et al42 | 2017 | Japan | 388 | I | EGFR 185 (47.7) | EGFR (19–21) | PCR | Multivariate |
| Kadota et al16 | 2016 | USA | 378 | I | EGFR 85 (22.5) | EGFR (18–21) | Sequenom | Univariate |
| 482 | I–II | KRAS 129 (27) | KRAS (2) | PCR | Multivariate | |||
| Isaka et al43 | 2016 | Japan | 202 | II–IIIA | EGFR 100 (49.5) | EGFR (19, 21) PCR | Multivariate | |
| Zheng et al17 | 2016 | China | 1,368 | I–IV | KRAS 118 (8.26) | KRAS (2) | RT-PCR, SEQ | Multivariate |
| Kaseda et al44 | 2017 | Japan | 162 | I | EGFR 81 (50), KRAS 17 (10.5) | EGFR (19, 21), KRAS (2) | PCR | Univariate |
| Sullivan et al45 | 2017 | USA | 131 | IA–IIB | No data | KRAS (6) | RT-PCR | Multivariate |
| Takamochi et al47 | 2017 | Japan | 939 | I–IV | EGFR 418 (44.5) | EGFR (18, 19, 21) | PCR | Multivariate |
| Yotsukura et al46 | 2017 | Japan | 369 | I–II | EGFR 160 (46.9) | EGFR (19, 21) | PCR | Multivariate |
Abbreviations: ARMS, amplification refractory mutation system; PCR, polymerase chain reaction; RFLP, restriction fragment length polymorphism; RT, reverse transcription; SEQ, sequencing.